ScripsAmerica Updates Status of 10K Filing TYSONS CORNER,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ScripsAmerica Updates Status of 10K Filing

TYSONS CORNER, Va., April 15, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB: SCRC ), a leading provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies, today announced that it will be unable to file its 2014 Annual Report on Form 10-K with the Securities and Exchange Commission by the extension deadline of April 15, 2015.

Due to the explosive growth in revenues, which rose to $30 million in 2014 from just $600,000 in 2013, the vast majority of which was generated over the last two quarters of 2014, our auditors have required additional time to perform the thorough analysis incumbent in an Audit. We are confident that our results of operations and financial position have been properly reflected in the preliminary results we have issued for both fiscal 2014 as well as the first quarter of fiscal 2015 as most recently disclosed in our April 13, 2015 presentation at the Growth Capital Expo. That presentation is available on our website at

http://www.snl.com/IRW/Presentations/4578348 .

Mr. Robert Schneiderman, Chief Executive Officer and Co-Founder, said, "The auditor's work on the 10-K filing has not interfered with our operations or our ability to execute our growth strategy. ScripsAmerica is fundamentally sound and is looking forward to a record 2015."

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com .

Joe Hassett Gregory FCA 610-228-2110

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Discovering Innovation: Smitty's Car Wash on Public Television

Updated Category News Views 332

Innovation at Smitty's Car Wash Viewers are in for an enlightening experience as the show "Empowered with Meg Ryan" spotlights Smitty's Car Wash, a pioneer in the express tunnel car wash industry. This segment promises to challenge traditional notions of car washing, showcasing how modern methods and technology integrate to create not just services, but transformative...

Continue Reading
ASPCA® Expands Veterinary Services with New Clinic Opening

Updated Category News Views 144

ASPCA® Opens New Community Veterinary Clinic in New York The ASPCA Community Veterinary Clinic, supported by The Rachael Ray Foundation, is set to meet the needs of many pets in the local area. This opening in New York City is a crucial advancement in providing vital veterinary care to communities in need. Veterinary Services That Are Within Reach Thousands of pets in...

Continue Reading
Big Boost for European Innovation with Novo Nordisk Foundation's Grant

Updated Category News Views 91

Novo Nordisk Foundation Boosts Innovation Funding In a groundbreaking move to enhance innovation in Europe, the Novo Nordisk Foundation is investing up to DKK 5.5 billion (approximately EUR 736 million) into the BioInnovation Institute (BII). This funding is set to play a transformative role in supporting entrepreneurs and startups within the life sciences sector....

Continue Reading
Legal Challenges for 3D Systems: Investor Action Recommended

Updated Category News Views 165

Overview of the Legal Situation Recent events surrounding 3D Systems Corporation have raised significant concerns among investors. The company is currently facing a class action lawsuit that alleges violations of securities laws. Investors in 3D Systems are encouraged to stay informed about the progress of this legal challenge and consider their options moving forward....

Continue Reading
Inhibikase Therapeutics Updates: Q2 2025 Financial Overview

Updated Category News Views 135

Inhibikase Therapeutics Q2 2025 Financial Update Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is making notable strides as a clinical-stage pharmaceutical company dedicated to developing innovative therapeutics aimed at addressing cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension (PAH). Recently, they announced their financial results for the second...

Continue Reading